In the dynamic landscape of modern biopharmaceuticals, the focus has shifted significantly toward the gut-organ axes, placing the human microbiome at the heart of therapeutic innovation. As a premier Contract Research Organization (CRO) dedicated to preclinical excellence, Creative Biolabs specializes in bridging the gap between complex microbial ecology and targeted drug delivery. Our expertise spans the development of live biotherapeutic products (LBPs), probiotic characterization, and sophisticated gut microbiota research.
Among our most advanced offerings is the Lactobacillus spp.-mediated RNAi Delivery Platform, a cutting-edge service designed to harness the natural colonizing power of lactic acid bacteria to deliver gene-silencing molecules directly to the mucosal interface. This service provides a non-invasive, site-specific alternative to traditional systemic RNAi delivery, overcoming the hurdles of instability and poor bioavailability.
Overview: Lactobacillus-mediated RNAi
RNA interference (RNAi) is a revolutionary biological process where double-stranded RNA (dsRNA) molecules inhibit gene expression by neutralizing targeted mRNA molecules. However, the delivery of these fragile RNA molecules to specific tissues, particularly the gastrointestinal tract, has historically been a significant challenge due to the harsh acidic environment of the stomach and the presence of ubiquitous RNases.
Our platform utilizes Lactobacillus spp. as a "living factory" and delivery vehicle. By engineering generally regarded as safe (GRAS) probiotic strains to express sequence-specific shRNA or dsRNA, we enable the continuous production and release of therapeutic RNAi triggers directly within the gut lumen. This approach allows for the precise knockdown of host genes (e.g., pro-inflammatory cytokines) or pathogen genes, providing a powerful tool for functional genomics and therapeutic validation in preclinical models.
Comprehensive Service Portfolio
We provide an "end-to-end" solution for researchers looking to utilize microbial vectors for gene silencing. Our service modules are modular and can be customized to suit specific research objectives:
Target Design and Strategy Consultation
Our scientists assist in the selection of optimal target sequences to maximize knockdown efficiency while minimizing off-target effects. We utilize advanced bioinformatics pipelines to design shRNA/dsRNA sequences tailored to your specific gene of interest.
Strain Engineering and Optimization
-
Strain Selection: Choose from our library of characterized Lactobacillus strains (e.g., L. plantarum, L. reuteri, L. casei) based on their colonization niche and persistence profiles.
-
Vector Construction: Sophisticated molecular cloning to integrate RNAi expression cassettes into the bacterial genome or stable plasmids.
-
Inducible Systems: We offer constitutive or inducible promoters (e.g., bile-acid or pH-responsive) to control the timing of RNAi production.
In Vitro Validation
Before moving to animal models, we verify the functionality of the engineered strains:
-
Expression Profiling: Quantifying the production of dsRNA/shRNA via qPCR and Northern Blot.
-
Cell-Based Assays: Co-culturing engineered Lactobacillus with intestinal epithelial cell lines (e.g., Caco-2) to demonstrate successful RNA uptake and target gene silencing.
Preclinical In Vivo Studies
We execute rigorous animal studies to evaluate the therapeutic potential of the RNAi-mediated probiotic:
-
Colonization Tracking: Monitoring the transit and localization of the engineered bacteria in the GI tract.
-
Efficacy Testing: Assessing phenotypic changes, such as reduction in inflammation markers or improvement in disease scores in models of IBD, metabolic syndrome, or colorectal cancer.
-
Safety & Toxicology: Evaluating the impact on the host's native microbiota and systemic health.
Related Products
To support your internal research, we offer a range of specialized products derived from our development pipeline:
-
Custom RNAi Expression Vectors: Specialized plasmids with various selection markers and promoter strengths compatible with multiple Lactobacillus species.
Applications
The versatility of our Lactobacillus-mediated RNAi service opens doors across various therapeutic and research areas:
-
Inflammatory Bowel Disease (IBD): Silencing TNF-α, IL-12, or other pro-inflammatory pathways directly in the gut mucosa.
-
Metabolic Disorders: Modulating host genes involved in lipid metabolism or glucose transport to study obesity and Type 2 Diabetes.
-
Infectious Disease: Targeting essential genes in gut pathogens (e.g., C. difficile or Salmonella) to inhibit virulence without broad-spectrum antibiotic use.
-
Gut-Brain Axis Research: Investigating how silencing specific enteric neurotransmitter receptors affects neurological behavior and health.
-
Cancer Immunotherapy: Localized delivery of RNAi to modulate the tumor microenvironment in colorectal cancer models.
Platform Advantages
Choosing a Lactobacillus-based system over traditional lipid nanoparticle (LNP) or viral delivery offers several distinct benefits:
Exceptional Stability
The bacterial cell wall protects the RNA cargo from gastric acid and enzymatic degradation, ensuring high-integrity delivery to the intestine.
Mucosal Adhesion
Lactobacillus species naturally adhere to the intestinal mucus layer, providing prolonged exposure of the RNAi molecules to the target epithelium.
Low Immunogenicity
As commensal organisms, these bacteria generally do not trigger the adverse immune responses often seen with viral vectors or synthetic carriers.
Cost-Effectiveness
"Living" delivery systems are self-replicating, reducing the need for repeated high-dose administrations of expensive synthetic RNAs.
Dual-Benefit Therapy
Beyond the RNAi effect, the host benefits from the intrinsic probiotic properties of the Lactobacillus carrier.
The use of Lactic Acid Bacteria (LAB) as delivery vehicles is grounded in decades of probiotic research and the "Generally Regarded as Safe" (GRAS) status granted by regulatory bodies. Unlike many other bacteria, Lactobacillus spp. do not produce endotoxins (LPS), making them ideal for therapeutic applications.
At Creative Biolabs, we understand that every drug development journey is unique. By integrating our deep knowledge of microbiome dynamics with advanced genetic engineering, we provide more than just a service; we provide a partnership dedicated to uncovering the next generation of biotherapeutics. Whether you are in the early stages of target validation or moving toward IND-enabling studies, our team is equipped to accelerate your progress with precision and reliability.
Would you like me to prepare a customized project proposal or a technical quote based on a specific gene target you are currently researching?
Frequently Asked Questions (FAQs)
How long does the engineering of a custom Lactobacillus strain take?
Typically, the process from sequence design to a validated "ready-to-use" strain takes 8 to 12 weeks, depending on the complexity of the genetic modifications.
Can these strains be used for systemic gene silencing?
While primarily designed for gastrointestinal and mucosal targets, emerging research suggests that gut-secreted factors can have systemic impacts. However, for direct targeting of organs like the liver or lungs, different delivery routes or vectors may be more appropriate.
How do you ensure the stability of the RNAi expression in the animal gut?
We utilize genomic integration techniques to ensure the RNAi cassette is passed down through generations of the bacteria without the need for antibiotic selection pressure in the host.
Is it possible to target multiple genes at once?
Yes, we can design polycistronic vectors capable of expressing multiple shRNAs, allowing for the simultaneous knockdown of several targets or pathways.
